Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples